EQUIPT: protocol of a comparative effectiveness research study evaluating cross-context transferability of economic evidence on tobacco control

Introduction Tobacco smoking claims 700 000 lives every year in Europe and the cost of tobacco smoking in the EU is estimated between €98 and €130 billion annually; direct medical care costs and indirect costs such as workday losses each represent half of this amount. Policymakers all across Europe are in need of bespoke information on the economic and wider returns of investing in evidence-based tobacco control, including smoking cessation agendas. EQUIPT is designed to test the transferability of one such economic evidence base—the English Tobacco Return on Investment (ROI) tool—to other EU member states. Methods and analysis EQUIPT is a multicentre, interdisciplinary comparative effectiveness research study in public health. The Tobacco ROI tool already developed in England by the National Institute for Health and Care Excellence (NICE) will be adapted to meet the needs of European decision-makers, following transferability criteria. Stakeholders' needs and intention to use ROI tools in sample countries (Germany, Hungary, Spain and the Netherlands) will be analysed through interviews and surveys and complemented by secondary analysis of the contextual and other factors. Informed by this contextual analysis, the next phase will develop country-specific ROI tools in sample countries using a mix of economic modelling and Visual Basic programming. The results from the country-specific ROI models will then be compared to derive policy proposals that are transferable to other EU states, from which a centralised web tool will be developed. This will then be made available to stakeholders to cater for different decision-making contexts across Europe. Ethics and dissemination The Brunel University Ethics Committee and relevant authorities in each of the participating countries approved the protocol. EQUIPT has a dedicated work package on dissemination, focusing on stakeholders’ communication needs. Results will be disseminated via peer-reviewed publications, e-learning resources and policy briefs.

[1]  H. Ross.  The Economics of Tobacco and Tobacco Control in the European Union." In Tobacco or Health in the European Union: Past, Present and Future , 2004 .

[2]  F. Pang,et al.  Generalisability in economic evaluation studies in healthcare: a review and case studies. , 2004, Health technology assessment.

[3]  S. Golder,et al.  Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment , 2012, PharmacoEconomics.

[4]  E. Rogers,et al.  Diffusion of innovations , 1964, Encyclopedia of Sport Management.

[5]  M. Mugford,et al.  The Social Support and Family Health Study: a randomised controlled trial and economic evaluation of two alternative forms of postnatal support for mothers living in disadvantaged inner-city areas. , 2004, Health technology assessment.

[6]  S Chapman,et al.  Tobacco Control , 1992, Journal of the Royal College of Physicians of London.

[7]  Franziska Wulf,et al.  Methods For The Economic Evaluation Of Health Care Programmes , 2016 .

[8]  M. Cowie.  National Institute for Health and Care Excellence. , 2015, European heart journal.

[9]  Hein de Vries,et al.  The general public's information needs and perceptions regarding hereditary cancer: an application of the Integrated Change Model. , 2005, Patient education and counseling.

[10]  Christopher J L Murray,et al.  WHO Framework Convention on Tobacco Control: development of an evidence based global public health treaty , 2003, BMJ : British Medical Journal.

[11]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[12]  Ron Goeree,et al.  Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another , 2007, Current medical research and opinion.

[13]  Bernie J O'Brien,et al.  Measures of importance for economic analysis based on decision modeling. , 2003, Journal of clinical epidemiology.

[14]  T O Jefferson,et al.  Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.

[15]  Raydel Valdés Salgado.  [The Framework Convention on Tobacco Control]. , 2003, Salud publica de Mexico.

[16]  Mark Sculpher,et al.  Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  N. Wareham,et al.  A translational framework for public health research , 2009, BMC public health.

[18]  R. Borland,et al.  The Economics of Tobacco and Tobacco Control , 2016 .

[19]  L. Joossens,et al.  The Tobacco Control Scale: a new scale to measure country activity , 2006, Tobacco Control.

[20]  Reiner Leidl,et al.  A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between Countries , 2012, PharmacoEconomics.

[21]  Z. Kaló,et al.  Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries. , 2012, European journal of cancer care.

[22]  C. Boehler.  Mind the Gap! - Geographic transferability of economic evaluation in health , 2012 .

[23]  Milton C Weinstein,et al.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.